secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABIOMED INC (—)
CIK:        0000815094
Form:       8-K
Filed at:   2022-12-22T23:59:59+00:00
Accession:  0001193125-22-311074
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Johnson & Johnson completes $17.1B acquisition of ABIOMED at $380/share plus CVR
--------------------------------------------------------------------------------

- Aggregate consideration approximately $17.1 billion; 25.8M shares (~57.1%) tendered and accepted.
- Per share: $380.00 cash plus a non-tradeable CVR entitling holders to up to $35.00 upon achieving specified milestones.
- Company becomes wholly owned subsidiary of Johnson & Johnson; shares removed from NASDAQ listing.
- CEO Michael Minogue, CFO Todd Trapp, and GC Marc Began terminated without cause; receive severance per agreements.
- Transaction bonuses: Trapp $6.18M, Began $6.07M; Trapp's CIC severance amended to include pro-rata target bonus plus two times target bonus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/815094/000119312522311074/0001193125-22-311074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/815094/000119312522311074/d353287d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-311074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer